{"id":8052,"date":"2023-03-01T18:37:52","date_gmt":"2023-03-01T17:37:52","guid":{"rendered":"https:\/\/www.afaf.asso.fr\/?p=8052"},"modified":"2023-03-01T18:38:43","modified_gmt":"2023-03-01T17:38:43","slug":"la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023","status":"publish","type":"post","link":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/","title":{"rendered":"La FDA approuve l&#8217;omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"8052\" class=\"elementor elementor-8052\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-50df2e2 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"50df2e2\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e880f51\" data-id=\"e880f51\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2497813 elementor-widget elementor-widget-text-editor\" data-id=\"2497813\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tL\u2019agence am\u00e9ricaine du m\u00e9dicament, la FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l&#8217;AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C&#8217;est un grand pas vers l&#8217;acc\u00e8s \u00e0 cette mol\u00e9cule en Europe aussi, par la suite, et \u00e0 d&#8217;autres mol\u00e9cules.\n\nPlus d\u2019infos bient\u00f4t lors de la rencontre annuelle AFAF!\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a8b09c5 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"a8b09c5\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5a5d188\" data-id=\"5a5d188\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2ad0755 elementor-widget elementor-widget-text-editor\" data-id=\"2ad0755\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>\u00ab Mardi 28 f\u00e9vrier 2023.<br \/><strong> Aujourd&#8217;hui, la FDA a annonc\u00e9 que SKYCLARYS (omaveloxolone) est approuv\u00e9 dans le traitement de l&#8217;ataxie de Friedreich. <\/strong><\/p><p>Vous trouverez le communiqu\u00e9 de presse du laboratoire Reata sur\u00a0 <a href=\"https:\/\/www.reatapharma.com\/investors\/news\/news-details\/2023\/Reata-Pharmaceuticals-Announces-FDA-Approval-of-SKYCLARYS-Omavaloxolone-the-First-and-Only-Drug-Indicated-for-Patients-with-Friedreichs-Ataxia\/default.aspx\" target=\"_blank\" rel=\"noopener\">https:\/\/www.reatapharma.com\/investors\/news\/news-details\/2023\/Reata-Pharmaceuticals-Announces-FDA-Approval-of-SKYCLARYS-Omavaloxolone-the-First-and-Only-Drug-Indicated-for-Patients-with-Friedreichs-Ataxia\/default.aspx<\/a><\/p><p>Lien vers le site de l\u2019agence am\u00e9ricaine du m\u00e9dicament, la <strong>FDA<\/strong> :<\/p><p><a href=\"https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&amp;ApplNo=216718\" target=\"_blank\" rel=\"noopener\">https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&amp;ApplNo=216718<\/a>.<strong><br \/><\/strong><\/p><p><strong>FARA<\/strong> travaille sur un suivi communautaire qui sera publi\u00e9 sous peu. Voici leur communication :<br \/><a href=\"https:\/\/www.curefa.org\/news-press-releases\/first-medication-to-treat-friedreich-s-ataxia-approved-on-rare-disease-day\" target=\"_blank\" rel=\"noopener\">https:\/\/www.curefa.org\/news-press-releases\/first-medication-to-treat-friedreich-s-ataxia-approved-on-rare-disease-day<\/a><\/p><p><strong>N&#8217;h\u00e9sitez pas \u00e0 utiliser la communication du FARA et \u00e0 la r\u00e9it\u00e9rer.<\/strong> \u00bb<\/p><p>Re\u00e7u de Myriam Rai, PhD<br \/>Director of Global Relations &amp; Initiatives<br \/>Friedreich&#8217;s Ataxia Research Alliance (FARA)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>L\u2019agence am\u00e9ricaine du m\u00e9dicament, la FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l&#8217;AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C&#8217;est un grand pas vers l&#8217;acc\u00e8s \u00e0 cette mol\u00e9cule en Europe aussi, par la suite, et \u00e0 d&#8217;autres mol\u00e9cules. Plus d\u2019infos bient\u00f4t lors de la rencontre annuelle AFAF! [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1656,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"ocean_front_end_style_editor":"no","ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"0","ocean_second_sidebar":"0","ocean_disable_margins":"on","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"0","ocean_custom_header_template":"0","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"0","ocean_menu_typo_font_family":"0","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"0","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"off","ocean_gallery_id":[],"footnotes":""},"categories":[44,43],"tags":[],"class_list":["post-8052","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-generales","category-informations_recherche","entry","has-media","owp-thumbs-layout-horizontal","owp-btn-normal","owp-tabs-layout-section","has-no-thumbnails"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La FDA approuve l&#039;omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023 - Association Fran\u00e7aise Ataxie de Friedreich<\/title>\n<meta name=\"description\" content=\"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l&#039;AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C&#039;est un grand pas vers l&#039;acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d&#039;autres mol\u00e9cules.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA approuve l&#039;omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023 - Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"og:description\" content=\"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l&#039;AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C&#039;est un grand pas vers l&#039;acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d&#039;autres mol\u00e9cules.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-01T17:37:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-01T17:38:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"467\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"afafadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"afafadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/\"},\"author\":{\"name\":\"afafadmin\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/5424e5cbe70a962cadb85c217d565d80\"},\"headline\":\"La FDA approuve l&#8217;omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023\",\"datePublished\":\"2023-03-01T17:37:52+00:00\",\"dateModified\":\"2023-03-01T17:38:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/\"},\"wordCount\":204,\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/actualite-afaf.png\",\"articleSection\":[\"Actualit\u00e9s g\u00e9n\u00e9rales\",\"Informations sur la recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/\",\"name\":\"La FDA approuve l'omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023 - Association Fran\u00e7aise Ataxie de Friedreich\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/actualite-afaf.png\",\"datePublished\":\"2023-03-01T17:37:52+00:00\",\"dateModified\":\"2023-03-01T17:38:43+00:00\",\"description\":\"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l'AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C'est un grand pas vers l'acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d'autres mol\u00e9cules.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/actualite-afaf.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/actualite-afaf.png\",\"width\":700,\"height\":467,\"caption\":\"actualit\u00e9s AFAF\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/01\\\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La FDA approuve l&rsquo;omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"description\":\"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.afaf.asso.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"width\":1181,\"height\":709,\"caption\":\"Association Fran\u00e7aise Ataxie de Friedreich\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/5424e5cbe70a962cadb85c217d565d80\",\"name\":\"afafadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g\",\"caption\":\"afafadmin\"},\"sameAs\":[\"https:\\\/\\\/www.afaf.asso.fr\"],\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/author\\\/afafadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA approuve l'omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023 - Association Fran\u00e7aise Ataxie de Friedreich","description":"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l'AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C'est un grand pas vers l'acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d'autres mol\u00e9cules.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/","og_locale":"fr_FR","og_type":"article","og_title":"La FDA approuve l'omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023 - Association Fran\u00e7aise Ataxie de Friedreich","og_description":"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l'AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C'est un grand pas vers l'acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d'autres mol\u00e9cules.","og_url":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/","og_site_name":"Association Fran\u00e7aise Ataxie de Friedreich","article_published_time":"2023-03-01T17:37:52+00:00","article_modified_time":"2023-03-01T17:38:43+00:00","og_image":[{"width":700,"height":467,"url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","type":"image\/png"}],"author":"afafadmin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"afafadmin","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/#article","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/"},"author":{"name":"afafadmin","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/5424e5cbe70a962cadb85c217d565d80"},"headline":"La FDA approuve l&#8217;omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023","datePublished":"2023-03-01T17:37:52+00:00","dateModified":"2023-03-01T17:38:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/"},"wordCount":204,"publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","articleSection":["Actualit\u00e9s g\u00e9n\u00e9rales","Informations sur la recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/","url":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/","name":"La FDA approuve l'omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023 - Association Fran\u00e7aise Ataxie de Friedreich","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","datePublished":"2023-03-01T17:37:52+00:00","dateModified":"2023-03-01T17:38:43+00:00","description":"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l'AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C'est un grand pas vers l'acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d'autres mol\u00e9cules.","breadcrumb":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/#primaryimage","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","width":700,"height":467,"caption":"actualit\u00e9s AFAF"},{"@type":"BreadcrumbList","@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/01\/la-fda-approuve-lomaveloxolone-comme-therapeutique-af-le-28-fevrier-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.afaf.asso.fr\/"},{"@type":"ListItem","position":2,"name":"La FDA approuve l&rsquo;omaveloxolone comme th\u00e9rapeutique AF, le 28 f\u00e9vrier 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.afaf.asso.fr\/#website","url":"https:\/\/www.afaf.asso.fr\/","name":"Association Fran\u00e7aise Ataxie de Friedreich","description":"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich","publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.afaf.asso.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.afaf.asso.fr\/#organization","name":"Association Fran\u00e7aise Ataxie de Friedreich","url":"https:\/\/www.afaf.asso.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","width":1181,"height":709,"caption":"Association Fran\u00e7aise Ataxie de Friedreich"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/5424e5cbe70a962cadb85c217d565d80","name":"afafadmin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g","caption":"afafadmin"},"sameAs":["https:\/\/www.afaf.asso.fr"],"url":"https:\/\/www.afaf.asso.fr\/author\/afafadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/8052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/comments?post=8052"}],"version-history":[{"count":0,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/8052\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media\/1656"}],"wp:attachment":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media?parent=8052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/categories?post=8052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/tags?post=8052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}